Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer
- 570 Downloads
Diagnosis of pancreatic cancer (PC) by using sensitive and specific biomarkers is considered necessary. MiRNAs are master regulators of gene expression and several biological processes, and they are dysregulated in various cancers, where they play a vital role in either cancer progression or suppression. So, this study was designed to investigate the role of plasma miR-22-3p, miR-642b-3p and miR-885-5p expression as possible diagnostic markers in PC patients as compared to serum CA19-9. In addition, the correlation of those miRNAs and CA19-9 with clinical characteristics of PC patients was analyzed.
The expression levels of selected miRNAs and serum CA19-9 concentration were determined for 35 patients with PDAC and 15 healthy controls by quantitative real-time RT-PCR and electro-chemiluminescence immune assay, respectively. The sensitivities of miRNAs as biomarkers of PC were evaluated and compared with CA19-9 using a receiver operating characteristic analysis.
The levels of three miRNAs (miR-22-3p, miR-642b-3p and miR-885-5p) and CA19-9 were significantly higher in PC patients, even those with early-stage disease (IB and IIB), than in healthy control. Both miRNAs and CA19-9 were associated with tumor stage. The high sensitivities of the three selected miRNAs and CA19-9 were observed.
The measurement of miR-22-3p, miR-642b-3p and miR-885-5p may prove to have clinical utility in diagnosis of PC. Those miRNAs are ideal early biomarkers for PC diagnosis. So, they can effectively be used with serum CA19-9 for PC screening in early tumor stage.
KeywordsPancreatic cancer miR-22-3p miR-642b-3p miR-885-5p CA19-9 and real-time RTPCR
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
All procedures performed in the study involving human participants were in accordance with the Local Ethical Committee of the Medical Research Institute, Alexandria University.
Written informed consent was obtained from all patients included in the study.
- Amirkande SY, Assmar M, Faribors MG, Noor AM (2015) The frequency of CA15-3, CA125, CA19-9 in Patients with Hepatitis B and C. Zahedan J Res Med Sci 17:29–33Google Scholar
- Kojima M, Sudo H, Kawauchi J, Takizawa S, Kondou S, Nobumasa H et al (2015) MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers. PLoS ONE 10:1–22Google Scholar
- Qureshi KM, Raman AK, Tan D, Fakih MG (2006) Leukemoid reaction in pancreatic cancer: a case report and review of the literature. JOP J Pancreas 7:631–634Google Scholar
- Tian Y, Gui J, Run W, Wen X, Zhang W, Zhang P (2012) Hepatic diseases related peripheral blood RNAs variation and their clinical significance. J Mol Biomark Diagn 3:39Google Scholar
- Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H et al (1999) Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 45:54–61PubMedGoogle Scholar
- Vietsch EE, Eijck CHJ, Wellstein A (2015) Circulating DNA and micro-RNA in patients with pancreatic cancer. Pancreat Disord Ther 5:1–11Google Scholar